Blurbs

Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Amgen (AMGN) and BioMarin Pharmaceutical (BMRN)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AmerisourceBergen (ABCResearch Report), Amgen (AMGNResearch Report) and BioMarin Pharmaceutical (BMRNResearch Report).

AmerisourceBergen (ABC)

Robert W. Baird analyst Eric Coldwell reiterated a Buy rating on AmerisourceBergen on June 1 and set a price target of $187.00. The company’s shares closed last Thursday at $148.21.

According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 9.5% and a 53.1% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, Cardinal Health, and IQVIA Holdings.

Currently, the analyst consensus on AmerisourceBergen is a Moderate Buy with an average price target of $171.17, implying a 14.2% upside from current levels. In a report issued on May 23, Cowen & Co. also maintained a Buy rating on the stock with a $171.00 price target.

See today’s best-performing stocks on TipRanks >>

Amgen (AMGN)

SVB Securities analyst David Risinger maintained a Hold rating on Amgen on May 31. The company’s shares closed last Thursday at $248.28.

According to TipRanks.com, Risinger is a 2-star analyst with an average return of 1.6% and a 75.0% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.

Currently, the analyst consensus on Amgen is a Hold with an average price target of $246.53, which is a -2.4% downside from current levels. In a report issued on May 23, Morgan Stanley also initiated coverage with a Hold rating on the stock with a $256.00 price target.

BioMarin Pharmaceutical (BMRN)

Robert W. Baird analyst Joel Beatty maintained a Buy rating on BioMarin Pharmaceutical on May 31 and set a price target of $112.00. The company’s shares closed last Thursday at $75.70.

According to TipRanks.com, Beatty is a 1-star analyst with an average return of -1.1% and a 41.0% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Arrowhead Pharmaceuticals, and Syndax Pharmaceuticals.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $113.67, representing a 52.6% upside. In a report issued on May 19, SVB Securities also reiterated a Buy rating on the stock with a $115.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed